Your browser doesn't support javascript.
loading
mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >=16 Years in the United States, February to May 2021
Sara S Kim; Jessie R Chung; Edward A Belongia; Huong Q McLean; Jennifer P King; Mary Patricia Nowalk; Richard K Zimmerman; Goundappa K Balasubramani; Emily T Martin; Arnold S Monto; Lois E Lamerato; Manjusha Gaglani; Michael E Smith; Kayan M Dunnigan; Michael L Jackson; Lisa A Jackson; Mark W Tenforde; Jennifer R Verani; Miwako Kobayashi; Stephanie Schrag; Manish M Patel; Brendan Flannery.
Afiliação
  • Sara S Kim; Centers for Disease Control and Prevention
  • Jessie R Chung; Centers for Disease Control and Prevention
  • Edward A Belongia; Marshfield Clinic Research Institute
  • Huong Q McLean; Marshfield Clinic Research Institute
  • Jennifer P King; Marshfield Clinic Research Institute
  • Mary Patricia Nowalk; University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center
  • Richard K Zimmerman; University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center
  • Goundappa K Balasubramani; University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center
  • Emily T Martin; University of Michigan
  • Arnold S Monto; University of Michigan
  • Lois E Lamerato; Henry Ford Health System
  • Manjusha Gaglani; Baylor Scott and White Health and Texas A&M University College of Medicine
  • Michael E Smith; Baylor Scott and White Health
  • Kayan M Dunnigan; Baylor Scott and White Health
  • Michael L Jackson; Kaiser Permanente Washington Health Research Institute
  • Lisa A Jackson; Kaiser Permanente Washington Health Research Institute
  • Mark W Tenforde; Centers for Disease Control and Prevention
  • Jennifer R Verani; Centers for Disease Control and Prevention
  • Miwako Kobayashi; Centers for Disease Control and Prevention
  • Stephanie Schrag; Centers for Disease Control and Prevention
  • Manish M Patel; Centers for Disease Control and Prevention
  • Brendan Flannery; Centers for Disease Control and Prevention
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21260647
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
Evaluations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged [≥]16 years, VE of mRNA vaccines against COVID-19 was 91% (95% CI 83-95) for full vaccination and 75% (95% CI 55-87) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.
Licença
cc_no
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Experimental_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Tipo de estudo: Experimental_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint